Nanobiotix (NANO) Price & Analysis

Compare

15 Followers

NANO Stock Chart & Stats

Day’s Range― - ―

52-Week Range€2.62 - €6.56

Previous CloseN/A

Volume30.64K

Average Volume (3M)180.74K

Market Cap

€310.57M

Enterprise ValueN/A

Total Cash (Recent Filing)€49.74M

Total Debt (Recent Filing)€50.90M

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Sep 04, 2025

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding47,943,150

10 Day Avg. Volume157,147

30 Day Avg. Volume180,740

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€7.75

Price Target Upside23.80% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentsMultiple clinical data updates are expected which could positively influence the stock's performance.

Financial ProspectsPotential milestone payments from Janssen Pharmaceuticals related to HNSCC and NSCLC could strengthen Nanobiotix's financial position.

PartnershipsNanobiotix's partner, Johnson & Johnson, initiated a Phase 2 study which could lead to a significant milestone payment if successful.

Bears Say

Financial ImpactRevenues in FY 24 were negatively impacted by a one-off recognition of a net liability linked to NANORAY-312's sponsorship transfer to J&J.

Risk FactorsRisks associated with the stock include clinical, commercial, financial, partnership, and intellectual property challenges.

Nanobiotix News

Nanobiotix SA – ADR trading resumes

09:35 EDT Nanobiotix (NBTX) SA – ADR trading resumes Published first on TheFly – the ultimate source for...

21d ago

NBTX

Nanobiotix SA – ADR trading halted, volatility trading pause

09:30 EDT Nanobiotix (NBTX) SA – ADR trading halted, volatility trading pause Published first on TheFly – the...

21d ago

NBTX

Nanobiotix announces regulatory harmonization, new patent for JNJ-1900

Nanobiotix (NBTX) announced two developments related to radioenhancer JNJ-1900, which is licensed by Janssen Pharmaceutica, a Johnson &...

1M ago

JNJ

NBTX

Promising Clinical Developments and Strategic Partnerships Propel Nanobiotix to a Buy Rating

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Nanobiotix (0QAV – Research Report), retaining the...

3M ago

NBTX

Nanobiotix’s Strategic Advancements and Financial Strength Bolster Buy Rating

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Nanobiotix (NBTX – Research Report) yesterday and set...

3M ago

NBTX

Nanobiotix’s NBTXR3: Promising Survival Benefits and Strategic Collaborations Justify Buy Rating

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix (0QAV – Research Report) and keeping...

3M ago

NBTX

Nanobiotix SA’s Positive Earnings Call Highlights Strategic Growth

Nanobiotix SA (($FR:NANO)) has held its Q4 earnings call. Read on for the main highlights of the call....

4M ago

Nanobiotix price target lowered to $8 from $12 at Guggenheim

Guggenheim lowered the firm’s price target on Nanobiotix (NBTX) to $8 from $12 and keeps a Buy rating...

4M ago

NBTX

Nanobiotix’s Promising Future: Buy Rating Backed by Data-Rich 2025 and Strategic Advancements

Nanobiotix (0QAV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

4M ago

NBTX

Nanobiotix: Strategic Partnerships and Clinical Advancements Drive Buy Rating

Stifel Nicolaus analyst Clémence Thiers has maintained their bullish stance on 0QAV stock, giving a Buy rating on...

4M ago

NBTX

Positive Clinical Data and Strategic Partnerships Drive Buy Rating for Nanobiotix

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Nanobiotix (0QAV – Research Report) today and set...

5M ago

NBTX

Nanobiotix’s Strategic Partnership and Financial Stability Justify Buy Rating

Analyst Jonathan Chang of Leerink Partners maintained a Buy rating on Nanobiotix (NBTX – Research Report), with a...

5M ago

NBTX

Nanobiotix’s Strategic and Financial Strength Bolstered by Janssen Licensing Agreement and Milestone Payments

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Nanobiotix (0QAV – Research Report) today and set...

5M ago

NBTX

Strategic Licensing Amendment with Janssen Bolsters Nanobiotix’s Financial Outlook and Justifies Buy Rating

Analyst Clémence Thiers of Stifel Nicolaus maintained a Buy rating on Nanobiotix (0QAV – Research Report), retaining the...

5M ago

NBTX

NANO FAQ

What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest stock price was €2.62 and its highest was €6.56 in the past 12 months.

What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €310.57M.

When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Sep 04, 2025 which is in 22 days.

How were Nanobiotix SA’s earnings last quarter?

Currently, no data Available

Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nanobiotix SA pay dividends?

Nanobiotix SA does not currently pay dividends.

What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate is -0.31.

How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 47,943,150 shares outstanding.

What happened to Nanobiotix SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in FR:NANO

Company Description

Nanobiotix SA

Nanobiotix (NANO) is a biotechnology company focused on developing innovative treatments for cancer using its proprietary nanotechnology platform. The company operates primarily in the oncology sector, aiming to enhance cancer therapies through its core product, NBTXR3, a nanoparticle designed to improve the efficacy of radiotherapy. By leveraging its expertise in nanomedicine, Nanobiotix seeks to provide solutions that address unmet medical needs in cancer treatment, ultimately improving patient outcomes.

Nanobiotix (NANO) Earnings & Revenues

Historic Earnings Reports

NANO Stock 12 Month Forecast

Average Price Target

€7.75

▲(23.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","6":"€6","11":"€11","3.5":"€3.5","8.5":"€8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,4.553846153846154,5.007692307692308,5.461538461538462,5.915384615384616,6.36923076923077,6.823076923076923,7.276923076923077,7.730769230769231,8.184615384615384,8.638461538461538,9.092307692307692,9.546153846153846,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,4.38076923076923,4.661538461538461,4.942307692307692,5.223076923076922,5.503846153846153,5.7846153846153845,6.065384615384615,6.346153846153846,6.6269230769230765,6.907692307692307,7.188461538461539,7.469230769230769,{"y":7.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,4.207692307692307,4.315384615384615,4.4230769230769225,4.530769230769231,4.638461538461538,4.746153846153846,4.8538461538461535,4.961538461538462,5.069230769230769,5.176923076923077,5.2846153846153845,5.392307692307693,{"y":5.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.25,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.445,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.968,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.812,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.464,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.244,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.975,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >